|| Print ||
|Articles - January 2013|
|Monday, December 10, 2012|
BY LINDA BAKER
Multiple sclerosis is an immune disorder in which the body mistakenly attacks the myelin sheath surrounding nerve fibers in the brain and spinal cord. The resulting neurological symptoms can range from numbness and tingling to paralysis. Although existing therapies reduce inflammation caused by MS, researchers have long sought to develop a therapy that will actually repair the neurological damage.
Enter Artielle ImmunoTherapeutics, a Portland biotech company that will launch an FDA phase-two clinical trial this year for a new therapy researchers say appears to also reverse the dysregulation of the immune system associated with MS and promotes nerve regeneration. The company takes its name from a phonetic rendering of its proprietary technology — recombinant T-cell receptor ligands.
“There is recovery from the disease,” says Arthur Vandenbark, a founding Artielle scientist and a neurology researcher affiliated with the Portland VA Medical Center and Oregon Health & Science University. “That’s what’s so exciting.” The phase-two trial is considered a critical milestone, as it will show the drug can work in MS patients — and not just in animal models. A phase-one trial, indicating the drug’s safety, was completed a few years ago. According to OHSU’s tech-transfer office, Artielle represents the first OHSU drug discovery to be commercialized this far in the clinical trial process by a company that was formed and has remained in Oregon.
Oregon can be a tough environment for homegrown biotech companies, which often struggle to locate investment capital. Founded eight years ago, Artielle is one of the success stories. It has raised $25 million of venture capital, including $2 million from Northwest Technology Ventures and Reference Capital Management, both located in Portland, and $11 million from Sanderling Ventures in the Bay Area, where Artielle CEO Peter McWilliams is based.
The phase-two trial is funded by the Department of Veterans Affairs and will help Artielle achieve its next financial goal: a buyout or partnership with a pharmaceutical company to help bring the product to market.
Only one in about 5,000 biotech startups develops a commercial drug, but the Artielle team thinks they have a shot. The market is saturated with purely anti-inflammatory drugs, says McWilliams. But Artielle’s technology goes further. “This is a disease-modifying agent,” he says.
|The more they change, the more they stay the same|
|The 2014 List: The Top 33 Large Companies to Work, For in Oregon|
|The 2014 List: The Top 34 Medium Companies to Work, For in Oregon|
|The 2014 List: The Top 33 Small Companies to Work, For in Oregon|
|The future of money|
|Cerberus Capital to buy Safeway|
|U.S. adds 175,000 jobs|
|Bitcoin creator revealed|
|Staples closing 225 stores|
|EU to offer aid package to Ukraine|
|Daily sugar intake 'should be halved'|
|White House reveals 2015 budget|
Living in the beautiful Pacific Northwest means enjoying our wonderful surroundings, while remaining aware of the multiple types of natural disaster threats that we face: winter storms, windstorms, floods, landslides, earthquakes, volcanoes and tsunamis.“
Oregon State University's hospitality degree program invests in next-generation leaders.
Allowing individuals to access their own healthcare options has created more difficulty instead of making things easier. There are so many examples that illustrate why agents are more important than ever in helping businesses and individuals determine the healthcare coverage that best fits their need.
The 2014 World Trademark Review 1000 (“WTR”) recently named Lane Powell as one of the top trademark law firms in Oregon and Washington, and Lane Powell attorneys Kenneth R. Davis II, Parna A. Mehrbani, Frances M. Jagla and Paul D. Swanson as top individuals in the practice.
Capital Pacific Bank, a Portland-based community bank serving businesses, professionals and nonprofit organizations, today announced that it has earned recognition as a Certified B Corporation by B Lab, a nonprofit organization dedicated to building a community of socially responsible businesses. The bank is one of six financial institutions across the country to achieve B Corp status.
On Thursday, April 3, from 8 a.m. to noon (registration begins at 7:30 a.m.), Lane Powell will team with Oregon Business magazine for a half-day seminar titled “Best Practices For Best Employers™: How to Become One of ‘Oregon’s Best Workplaces’ Starting Today!”